Search results
Kansas attorney general sues Pfizer over COVID vaccine, company responds
KSNT Topeka via Yahoo News· 1 day agoRelated video: Class action lawsuits – what are they, and should you join one? TOPEKA (KSNT) –...
MSD competes with Pfizer in pneumococcal vaccine market after FDA approval
Pharmaceutical Technology via Yahoo Finance· 7 hours agoThis includes the eight unique serotypes, 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B compared to other...
Pfizer Inc. (NYSE:PFE) Stake Boosted by Wellington Management Group LLP
ETF DAILY NEWS· 2 days agoWellington Management Group LLP lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoPfizer disclosed on May 7 that a child participating in another...
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading...
Benzinga· 1 day agoThe state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its ...
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 4 days agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 6 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 5 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Brown Shipley& Co Ltd Has $592,000 Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoBrown Shipley& Co Ltd reduced its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.9% during the fourth quarter, according to the company in its most recent ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 5 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...